Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Challenging ΔCD19 selected inducible Caspase9-CAR.CD33 T-cells with programmed-death-ligand-1 enriched leukemia blasts resulted in significant killing like observed for the programmed-death-ligand-1 negative leukemic blasts fraction.
|
27907031 |
2016 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Short TSLPR CAR treatment of mice engrafted with a TSLPR-expressing ALL cell line induced leukemia cytotoxicity with efficacy comparable with that of CD19 CAR T cells.
|
26041741 |
2015 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The incidence of leukemia in these mice varied from 5% to 50%, dependent on the Cre-driving promoter (Cd19, Mb1, or Mx1) used to induce E2A-PBX1 expression.
|
26301816 |
2015 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD45RA(-) cells that were transduced with anti-CD19 CAR containing 4-1BB and CD3ζ signaling domains effectively lysed MLL-rearranged leukemia cell lines and primary blasts in vitro.
|
24888271 |
2015 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In MLL-AF4 patients, CD34(+)CD38(+)CD19(+) and CD34(-)CD19(+) cells initiated leukemia, and in MLL-AF9 patients, CD34(-)CD19(+) cells were LICs.
|
25538041 |
2015 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Administration of CD19-specific CAR-modified T cells that target B cell non-Hodgkin lymphomas and leukemia has been remarkably effective in recent clinical trials, energizing the field and stimulating new efforts to identify the critical parameters of CAR design and T cell engineering that are necessary for effective cancer therapy.
|
24338745 |
2014 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of anti-CD19 chimeric signaling receptors can enhance NK-cell reactivity against CD19+ leukemia and lymphoma cells.
|
23296936 |
2013 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The observed in vitro and in vivo anti-leukemic potency of the αCD19-AON immunoconjugate provides the first preclinical proof-of-principle that t(1;19)(+) high risk B-lineage ALL can be treated with leukemia-specific biotherapeutic agents that knock-down E2A-PBX1 expression.
|
22990208 |
2013 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adoptive immunotherapy with the use of chimeric antigen receptor (CAR)-engineered T cells specific for CD19 has shown promising results for the treatment of B-cell lymphomas and leukemia.
|
23992830 |
2013 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19(+) leukemia xenografts in mice were reduced with CAR(+)γδ T cells compared with control mice.
|
23295945 |
2013 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
B cell chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is a clonal expansion of CD5(+)CD19(+) B lymphocytes.
|
23296468 |
2013 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Relative surface CD19 expression across the xenograft panel significantly correlated with leukemia progression delay and objective response measure scores.
|
23426279 |
2013 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.
|
23233573 |
2012 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unexpectedly, a single injection of CD19 RNA CAR T cells reduced disease burden within 1 day after administration, resulting in a significant prolongation of survival in an aggressive leukemia xenograft model.
|
21838572 |
2011 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this murine model, we identified a new, Rag1-independent leukemia-initiating mechanism originating from a Sca1(+)CD19(+) precursor cell population and showed that Notch1 expression accelerates the cells' self-renewal capacity in vitro.
|
21622646 |
2011 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that UCB-19BBzeta and UCB-28BBzeta T cells exhibited more cytotoxicity to CD19(+) leukemia and lymphoma cell lines than UCB-19zeta and UCB-1928zeta, although differences in secretion of interleukin-2 and interferon-gamma by these T cells were not evident.
|
19719389 |
2010 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD34(+)CD38(-)CD19(+), CD34(+)38(+)CD19(+), and CD34(-)CD38(+)CD19(+) fractions could self-renew and transfer the leukemia, whereas the CD34(-)CD38(+)CD19(+) fraction did not stably propagate in NOD/SCID mice.
|
20028384 |
2010 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that leukemia-initiating cells in childhood B-ALL have a primitive CD133(+)/CD19(-) and CD38(-) phenotype.
|
19147788 |
2009 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In vitro-stimulated NK cells from healthy donors and pediatric leukemia patients were gene modified with CD19 or G(D2)-specific chimeric receptors containing either the T-cell receptor zeta or 2B4 endodomain alone or combined.
|
19638467 |
2009 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Over-expression of human TCL1, a known CLL oncogene in murine B-cells leads to the development of mature CD19+/CD5+/IgM+ clonal leukemia with a disease phenotype similar to that seen in human CLL.
|
19901553 |
2009 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that T cells genetically modified with a replication-defective gammaretroviral vector derived from the Moloney murine leukemia virus encoding a chimeric antigen receptor (CAR) targeted to CD19 (1928z) can be expanded with Dynabeads CD3/CD28.
|
19238016 |
2009 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
|
18829563 |
2008 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The engineered CD4(+) T cells and CD8(+) T cells both exhibited specific cytotoxicity against CD19(+) leukemia and lymphoma cell lines, as well as against CD19 transfectants, and produced high-levels of antigen-dependent Th1 (but not Th2) cytokines.
|
18227839 |
2008 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MP1-specific CTLs are amenable to subsequent genetic modification to express a CD19-specific CAR, designated CD19R, and acquire HLA-unrestricted reactivity toward CD19(+) leukemia and lymphoma tumor targets while maintaining HLA-restricted MP1 specificity.
|
15507526 |
2005 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunophenotyping of the first leukemia sample revealed a mixed lineage leukemia immunophenotype with positivity for terminal deoxynucleotidyl transferase (TdT), CD13 and CD19; the second sample revealed solely myeloid characteristics with positivity for CD13, CD41 and CD61, whereas TdT was negative.
|
15863212 |
2005 |